Parthenon Therapeutics
Ziyin Wang is a Bioinformatics Co-op at Parthenon Therapeutics since June 2022, bringing valuable experience from previous roles, including Laboratory Research Intern at Tsinghua University and Central China Normal University, and Laboratory Assistant at Wuhan Center for Disease Control & Prevention. Ziyin holds a Master of Science in Bioinformatics from Northeastern University, completed in December 2022, and a Bachelor of Science in Biotechnology from Central China Normal University, earned in June 2019.
Parthenon Therapeutics
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.